References
- 1. Romania in Global Cancer Statistics 2018. Oncology Today. Available at: https://www.medichub.ro/reviste/oncolog-hematolog-ro/romania-in-global-cancer-statistics-2018-id-2019-cmsid-68.
- 2. Tereanu C, Baili P, Berrino F, et al. Recent trends of cancer mortality in Romanian adults: Mortality is still increasing, although young adults do better than the middle-aged and elderly population. Eur J Cancer Prev. 2013;22:199-209.10.1097/CEJ.0b013e3283581d9022968450
- 3. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Breast screening: The facts - Or maybe not. BMJ. 2009;338:446-448.10.1136/bmj.b8619174442
- 4. Cardoso F, Cataliotti L, Costa A, et al. European Breast Cancer Conference manifesto on breast centres/units. Eur J Cancer. 2017;72:244-250.10.1016/j.ejca.2016.10.02328064097
- 5. Travasso C. Panel issues advice on early detection of oral, breast, and cervical cancers in India. BMJ. 2015;351:h3807.10.1136/bmj.h380726170274
- 6. Britton P, Sinnatamby R. Investigation of suspected breast cancer. Br Med J. 2007;335:347-348.10.1136/bmj.39234.386470.BE194946017703045
- 7. John M. Eisenberg Center for Clinical Decisions and Communications Science. Core-Needle Biopsy for Breast Abnormalities. In: Comparative Effectiveness Review Summary Guides for Clinicians. 2007. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27336126.
- 8. National Guideline Alliance (UK). Early and Locally Advanced Breast Cancer: Diagnosis and Management.2018. Available at: https://www.ncbi.nlm.nih.gov/books/NBK519155/.
- 9. Jeibouei S, Akbari ME, Kalbasi A, et al. Personalized medicine in breast cancer : pharmacogenomics approaches. Pharmgenomics Pers Med. 2019;12:59-73.10.2147/PGPM.S167886654974731213877
- 10. Chan CWH, Law BMH, So WKW, Chow KM, Waye MMY. Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update. Int J Mol Sci. 2017;18:2324.10.3390/ijms18112423571339129140300
- 11. Balic M, Thomssen C, Würstlein R, Gnant M, Harbeck N. St. Gallen/Vienna 2019: A brief summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care. 2019;14:103-110.10.1159/000499931688610831798382
- 12. Morigi C. Tailored Treatments for Patients With Early Breast Cancer. ecancer. 2017;11:1-12.10.3332/ecancer.2017.732540622228491135
- 13. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver M. WHO Classification of Tumours of the Breast. Fourth Edition, Geneva, Switzerland: WHO Press.; 2012.
- 14. Who Classification of Tumours Editorial Board. Breast Tumours. Lyon (France) Internation Agency for Research on Cancer; 2019. (WHO Classification of Tumours Series, 5th Ed.; Vol. 2).
- 15. Hoon Tan P, Ellis I, Allison K, et al. The 2019 WHO classification of tumours of the breast. Histopathology. 2020. [Ahead of print]
- 16. Fitzgibbons PL, Connolly JL, Edgerton M, MD, Simpson MR. Protocol for the examination of specimens From patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2020. [Ahead of print]
- 17. Untch M, Gerber B, Harbeck N, et al. 13th St. Gallen international breast cancer conference 2013: Primary therapy of early breast cancer evidence, controversies, consensus - Opinion of a German team of experts (Zurich 2013). Breast Care. 2013;8:221-229.10.1159/000351692372863424415975
- 18. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194-1220.10.1093/annonc/mdz173
- 19. Jorns JM. Challenges in routine estrogen receptor, progesterone receptor, and HER2/neu evaluation. Arch Pathol Lab Med. 2019;143:1444-1449.10.5858/arpa.2019-0205-RA
- 20. Fitzgibbons PL, Bartley AN, Connolly JL. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med. 2020. [Ahead of print]
- 21. Bucure C. Luna Internațională de C onștientizare d espre Cancerul de Sân (LICCS) 1-31 Octombrie 2019 Analiza de Situație. 2019:1-16. Available at: http://insp.gov.ro/sites/cnepss/wp-content/uploads/2019/10/Analiza-desituatie.pdf.
- 22. Pant K, Dutta U. Understanding and management of male breast cancer: A critical review. Med Oncol. 2008;25:294-298.10.1007/s12032-007-9034-y
- 23. Schünemann HJ, Lerda D, Quinn C, et al. Breast cancer screening and diagnosis: A synopsis of the european breast guidelines. Ann Intern Med. 2020;172:46-56.10.7326/M19-2125
- 24. Güth U, Huang DJ, Huber M, et al. Tumor size and detection in breast cancer: Self-examination and clinical breast examination are at their limit. Cancer Detect Prev. 2008;32:224-228.10.1016/j.cdp.2008.04.002
- 25. Shaevitch D, Taghipour S, Miller A, Montgomery N, Harvey B. Tumor size distribution of invasive breast cancers and the sensitivity of screening methods in the Canadian National Breast Screening Study. J Cancer Res Ther. 2017;13:562-569.
- 26. European Comission E. Breast Cancer and Cervical Cancer Screenings.; 2017. Available at: https://ec.europa.eu/eurostat/web/products-eurostat-news/-/DDN-20200109-1.
- 27. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181-187.10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
- 28. Orang E, Marzony ET, Afsharfard A. Predictive role of tumor size in breast cancer with axillary lymph node involvement - can size of primary tumor be used to omit an unnecessary axillary lymph node dissection? Asian Pacific J Cancer Prev. 2013;14:717-722.
- 29. Michaelson JS, Silverstein M, Sgroi D, et al. The Effect of Tumor Size and Lymph Node Status on Breast Carcinoma Lethality. Cancer. 2003;98:2133-2143.10.1002/cncr.11765
- 30. Narod SA. Tumour size predicts long-term survival among women with lymph node-positive breast cancer. Curr Oncol Vol. 2012;19:249-253.10.3747/co.19.1043
- 31. Laura S, Coombs NJ, Ung O, Boyages J. Tumour size as a predictor of axillary node metastases in patients with breast cancer. ANZ J Surg. 2006;76:1002-1006.10.1111/j.1445-2197.2006.03918.x
- 32. Sopik V, Narod SA. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat. 2018;170:647-656.10.1007/s10549-018-4796-9
- 33. Rambau P, Chalya P, Manyama M, Jackson K. Pathological features of Breast Cancer seen in Northwestern Tanzania: A nine years retrospective study. BMC Res Notes. 2011;4:214.10.1186/1756-0500-4-214315583521696617
- 34. Bonnier P, Romain S, Charpin C, et al. Age as a prognostic factor in breast cancer: Relationship to pathologic and biologic features. Int J Cancer. 1995;62:138-144.10.1002/ijc.29106202057622286
- 35. Alieldin NH, Abo-Elazm OM, Bilal D, et al. Age at diagnosis in women with non-metastatic breast cancer: Is it related to prognosis? J Egypt Natl Canc Inst. 2014;26:23-30.
- 36. Nelson H, Zakher B, Cantor A, et al. Risk Factors for Breast Cancer for Women Aged 40 to 49 Years A Systematic Review and Meta-analysis. Ann Intern Med. 2012;156:635-648.10.7326/0003-4819-156-9-201205010-00006356146722547473
- 37. Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat. 2017;165:193-200.10.1007/s10549-017-4325-2551131328578505
- 38. Rummel S, Hueman MT, Costantino N, Shriver CD, Ellsworth RE. Tumour location within the breast: Does tumour site have prognostic ability? Ecancermedicalscience. 2015;9:1-10.
- 39. Kroman N, Wohlfahrt J, Mouridsen HT, Melbye M. Influence of tumor location on breast cancer prognosis. Int J Cancer. 2003;105:542-545.10.1002/ijc.1111612712447
- 40. Sohn VY, Arthurs ZM, Sebesta JA, Brown TA. Primary tumor location impacts breast cancer survival. Am J Surg. 2008;195:641-644.10.1016/j.amjsurg.2007.12.03918424280
- 41. Geisel J, Raghu M, Hooley R. The Role of Ultrasound in Breast Cancer Screening: The Case for and Against Ultrasound. Semin Ultrasound, CT MRI. 2018;39:25-34.10.1053/j.sult.2017.09.00629317037
- 42. Jacklyn G, McGeechan K, Houssami N, Bell K, Glasziou PP, Barratt A. Overdiagnosis due to screening mammography for women aged 40 years and over. Cochrane Database Syst Rev. 2018;2018:CD013076.10.1002/14651858.CD013076
- 43. HD N, A C, L H, et al. Screening for Breast Cancer: A Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. In: Evidence Syntheses. Vol 124.; 2016. Available at: http://europepmc.org/abstract/med/26889531.
- 44. Makki J. Diversity of breast carcinoma: Histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015;8:23-31.10.4137/CPath.S31563468932626740749
- 45. Klimberg VS., Rivere A. Ultrasound image-guided core biopsy of the breast. Chinese Clin Oncol. 2016;5:1-9.
- 46. Julia Y.S. Tsang P and GMT. Molecular Classification of Breast Cancer. Adv Anat Pathol. 2020;27(1):27-35.10.1097/PAP.000000000000023231045583
- 47. Hamza AA, Idris SA, Al-haj MB, Mohammed AA. Prognostication of breast cancer using Nottingham Prognostic Index in Sudanese patients. 2014;2:1-5.
- 48. Thomas JSJ, Kerr GR, Jack WJL, et al. Histological grading of invasive breast carcinoma - A simplification of existing methods in a large conservation series with long-term follow-up. Histopathology. 2009;55:724-731.10.1111/j.1365-2559.2009.03429.x19845790
- 49. Megha T, Neri A, Malagnino V, et al. Traditional and new prognosticators in breast cancer: Nottingham index, Mib-1 and estrogen receptor signaling remain the best predictors of relapse and survival in a series of 289 cases. Cancer Biol Ther. 2010;9:266-273.10.4161/cbt.9.4.1065920026902
- 50. Oluogun WA, Adedokun KA, Oyenike MA, Adeyeba OA. Histological classification, grading, staging, and prognostic indexing of female breast cancer in an African population: A 10-year retrospective study. Int J Health Sci (Qassim). 2019;13:3-9.
- 51. Salhia B, Tapia C, Ishak EA, et al. Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Womens Health. 2011;11:44.10.1186/1472-6874-11-44320428321961708
- 52. Kermani T, Kermani I, Faham Z, Dolatkhah R. Ki-67 status in patients with primary breast cancer and its relationship with other prognostic factors. Biomed Res Ther. 2019;6(2 SE-Research articles).10.15419/bmrat.v6i2.520
- 53. Kasangian AA, Gherardi G, Biagioli E, et al. The prognostic role of tumor size in early breast cancer in the era of molecular biology. PLoS One. 2017;12:e0189127.10.1371/journal.pone.0189127571850529211792
- 54. Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:290-303.10.3322/caac.2139328294295
- 55. Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38:1346-1366.10.1200/JCO.19.0230931928404
- 56. Kuijer A, King TA. Age, molecular subtypes and local therapy decision-making. Breast. 2017;34:S70-S77.10.1016/j.breast.2017.06.03228666919